3 Firms Build Jazz Pharmaceuticals' $935M Chimerix Buy
By Jade Martinez-Pogue · March 5, 2025, 12:47 PM EST
Jazz Pharmaceuticals on Wednesday revealed plans to acquire biopharmaceutical company Chimerix in a $935 million deal built by three law firms that will further diversify Jazz's oncology portfolio....
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login